InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Enters into $1.2M Agreement for Exercise of Warrants
Predictive Oncology (NASDAQ: POAI), a leader in artificial-intelligence (“AI”)-driven drug discovery and biologics, has entered into a definitive agreement for the exercise of certain existing warrants. The agreement outlines the purchase of up to 958,117 shares of its common stock at a reduced exercise price of $1.32 per share; the shares were originally issued in February 2021, June 2021 and May 2022. Predictive Oncology anticipates…